Clinical Trial Update: Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 dose-finding trial of E2609 in mild cognitive impairment and Alzheimer's-related dementia was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia Due to Alzheimer Disease

Drugs mentioned

• E2609

Snippet

Sponsor: Eisai Inc. | Conditions: Alzheimer Disease, Dementia, Alzheimer Type | Phase 2 | Status: TERMINATED | Results posted: 2021-03-05